April 6, 2026

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex,Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11

We enclose a copy of the Press Release that is being issued by the Company in connection with an announcement of positive top-line results for Phase 3 study of Omalizumab Biosimilar BP11 by CuraTeQ Biologics Private Limited, a 100% subsidiary.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.04.06 15:38:30 +05'30'

B. Adi Reddy
Company Secretary

Encl: as above

Hyderabad, India, April 6, 2026

CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd and a biopharmaceutical company developing biosimilars, today announced positive top-line results from its Phase 3 study of BP11, an investigational biosimilar to Xolair® (omalizumab). The study successfully met all primary endpoints, showing high comparability to the reference product in patients with chronic spontaneous urticaria (CSU) at the 300 mg dose.

The trial was conducted in 608 patients across approximately 80 sites in seven European countries and India, evaluating change from baseline in ISS7 (7-point Itch Severity Score) at Week 12, the main primary endpoint applicable for both FDA and EMA approvals. Results demonstrated precise equivalence, with tight confidence intervals well within the predefined margins (-2.5 to 2.0). The co-primary endpoint of relative potency, based on change from baseline in ISS7 at Week 12 using a 4-point assay, also met its criteria, demonstrating parallelism between BP11 and Xolair across dose levels. These outcomes reflect well-contained variability, robustness of data, and strong efficacy alignment. The results support regulatory submissions targeting CSU, allergic asthma, and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps).

“These Phase 3 results with narrow confidence intervals validate our clinical strategy and the team’s execution in delivering a high-quality biosimilar. Detailed results will be submitted for regulatory review and presented at upcoming medical conferences,” said **Dr. Arpitkumar Prajapati, Head of Clinical Development**.

“BP11 demonstrates comparable efficacy and safety to Xolair, paving the way for patient access to affordable treatment options. We are planning to complete filing of BP11 with both EMA and FDA by the end of Q2 2026,” said **Dr. Disha Dadke, Head of R&D and Regulatory Sciences**.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Investor Relations | Corporate Communications
Phone: +91 40 66751211 | 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.04.06 15:39:16 +05'30'